Please assess the completion status of the following clinical trial:

Trial Title: Immune Reconstitution in Tuberculosis Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~HIV negative patients, adult patients \>18 years who has not started anti-TB therapy.~Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputum-negative clinical TB cases (defined according to the WHO 2006 criteria for sputum smear-negative TB ie. clinical symptoms of TB, chest X-ray findings and response to standard treatment).~Exclusion Criteria:~Patients who have already started treatment with anti-TB drugs for more that 5 days.~HIV-positive patients.~History of anti-TB treatment in the past 2 years.~Local extra-pulmonary TB in the absence of lung manifestations.~Hypercalcaemia (serum calcium \> 3 mmol/L) identified at baseline.~Pregnant and breast feeding women.~Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate) (Type: ACTIVE_COMPARATOR): Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
- Placebo tablets (Type: PLACEBO_COMPARATOR): Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).